TO: Ambulance Services Providers
              Fire Departments
              Hospitals, Base and Receiving
              Training Centers

FROM: Humberto Ochoa, MD   *HROchoa M.D.*
              EMS Medical Director

RE: 2012 REMSA Policy Manual

DATE: March 31, 2012

The 2012 REMSA Policy Manual will go into effect Sunday, April 01, 2012. Please review the changes outlined below.

Policy 4103 – Calculation Chart - http://remsa.us/policy/2012/4103.pdf
The BH will decide whether to use the initial or repeat dose of Amiodarone and/or Lidocaine given to patients with pulses. For clarity, there is now a Conscious IO Pain row under Lidocaine reflecting the standing order for this found in the Universal Patient Treatment Protocol. Energy settings are no longer on the back of page 4 as they have been pushed onto page 5. For clarity there is now an Eclampsia row under Mag Sulfate.

Midazolam dosing has been cut in half, and all standing orders have been changed to allow a single repetition by standing order. This was done to address fears that the dose was too large while leaving the total dose by standing order unchanged. This also resolves issues with IN volumes. The treatment protocols that were updated to reflect this repeat of Midazolam by standing order include: 4403, 4404, 4405, 4408, 4502, and 4603. For clarity there is now a "Related to CPAP" row under Midazolam.

For clarity there is now a "IN per Nostril" row under Naloxone. The notation "IN x2" serves as a reminder that a single dose requires the stated dose to be given twice, once per nostril, to deal with volumes by the IN route. This is now described in the Calculation Chart's introduction. Maximum IM volumes are addressed in a similar fashion. Please reread the introductory statements included in the Calculation Chart as they have changed to address these clarifications.

Policy 7701 – Patient Care Reports and Records - http://remsa.us/policy/2012/7701.pdf
Patient Care Documentation Standards has reverted to our current policy and will return to the Policy Review Forum for further review.

The last page of the Universal Patient has also been modified to address this reversion:
http://remsa.us/policy/2012/4102.pdf

Policy 3307 – Alternative Medications - http://remsa.us/policy/2012/3307.pdf
- This policy was written to offer alternatives when dealing with supply shortages.

Zofran Administration to children
The following policies have been changed to satisfy questions about the safety and efficacy of giving Zofran to children.

These changes no longer allow for Zofran administration below Broselow Orange (24 kg) unless specifically ordered by a base hospital.

4103 Calculation Chart - http://remsa.us/policy/2012/4103.pdf

4504 Nausea and/or Vomiting - http://remsa.us/policy/2012/4504.pdf

7501 Administration of Ondansetron - http://remsa.us/policy/2012/7501.pdf

Policy 6101 – Prehospital Receiving Centers
- This policy has been removed and put on hold; it will return to the Policy Review Forum for further review.

All medication and or dosage changes have been fully incorporated into policy **4103 Calculation Chart** http://remsa.us/policy/2012/4103.pdf